Table 3.
Comparison between tenascin-X and established diagnostic markers in differentiating malignant mesothelioma (MM) from ovarian/peritoneal carcinoma (OC/PPC) and breast carcinoma in effusions (n=130) a
| Antibody (target tumor) | Number of staining cases (%) b | Sensitivity c | Specificity c | ||
|---|---|---|---|---|---|
| OC/PPC | Breast | Mesothelioma | |||
| Ber-EP4 (carcinoma) | 47/47 (100%) | 45/47 (96%) | 13/36 (36%) | 98% | 64% |
| B72.3 (carcinoma) | 42/47 (89%) | 23/47 (49%) | 0/36 (0%) | 69% | 100% |
| EMA - membrane (MM) | 0/47 (0%) | 0/47 (0%) | 33/36 (92%) | 92% | 100% |
| EMA - cytoplasm + membrane (carcinoma) | 47/47 (100%) | 47/47 (100%) | 2/36 (6%) | 100% | 94% |
| Calretinin (MM) | 9/47 (19%) | 11/47 (23%) | 35/36 (97%) | 97% | 79% |
| Tenascin-X (MM) | 5/47 (11%) | 15/47 (32%) | 33/36 (92%) | 92% | 79% |
a
Immunohistochemistry performed on a different specimen in 6 of 136 cases, which are therefore not shown in this table.
b
Any number of cells
c
For the differentiation between carcinoma and mesothelioma